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Abstract
Adverse cardiac remodeling leads to impaired ventricular function and heart failure, remaining a major cause of
mortality and morbidity in patients with acute myocardial infarction. It have been shown that, even if all the
recommended therapies for ST-segment elevation myocardial infarction are performed, one third of patients
undergoes progressive cardiac remodeling that represents morphological basis for following heart failure. The need
to extend our knowledge about factors leading to different clinical scenarios of myocardial infarction and following
complications has resulted in a research of immuno-inflammatory pathways and molecular activities as the basis for
post-infarction remodeling. Recently, macrophages (cells of the innate immune system) have become a subject of
scientific interest under both normal and pathological conditions. Macrophages, besides their role in host
protection and tissue homeostasis, play an important role in pathophysiological processes induced by myocardial
infarction. In this article we summarize data about the function of monocytes and macrophages plasticity in
myocardial infarction and outline potential role of these cells as effective targets to control processes of
inflammation, cardiac remodeling and healing following acute coronary event.
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Background
Recent data suggest that modern methods of interventional
and pharmacological therapies have already implemented
their potential to limit infarct size, reduce mortality and im-
prove contractile function in patients during and after acute
myocardial infarction [1, 2]. Cardiac remodeling following
myocardial infarction is a process of alterations in cardiac
geometry, function and structure, which is considered to be
a universal response to an increased wall stress or loss of
the viable myocardium [3, 4]. It leads to impaired ventricu-
lar function and heart failure, remaining a major cause of
mortality and morbidity [5–8].
During the last decade both experimental and clinical
studies have been identifying several modified and un-
modified predictors of adverse cardiac remodeling [9–12].
Obviously, not all experimental data can be extrapolated
to the clinical data. It is critical to underscore that reperfu-
sion time is a cornerstone factor determining post-
infarction cardiac remodeling [1, 4, 13]. The response to
ischemic injury in infarct area and in the remote viable
myocardium has a definite time sequence. However,
different severity grades of cardiac remodeling develop.
But at the same time, the processes of cardiac healing and
remodeling, even in similar clinical scenarios, under equal
conditions such as infarct size, location, clinic period prior
to treatment, therapy strategy, age - occur in different
ways [4, 14]. Bolognese [13] et al. and others [4] have
shown that, even if all the recommended therapies for
ST-segment elevation myocardial infarction are
performed, one third of patients undergo progressive
cardiac remodeling that represents morphological basis
for following heart failure.
In the era of reperfusion treatment two paradigms
dealing with mechanisms of cardiac remodeling after
myocardial infarction have been formed [15] (Fig. 1a).
According to the first paradigm, in the early phase of
injury, ventricular remodeling is an effect of infarct
expansion (process of myocardial wall thinning and
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dilatation); and in the later phase, it is secondary in regard
to surviving myocardium reconstruction involving reactive
myocyte hypertrophy, interstitial fibrosis and left ventricu-
lar dilatation [16, 17]. The second paradigm is based on
the idea, that changes of the extracellular collagen matrix
in both infarct and non-infarct zones of myocardium play
a major role in cardiac remodeling [18, 19].
Over the last decade the improvement and develop-
ment of medical technology have led to rise of attention,
in particular, to the second paradigm. It has become
clear that a huge number of endogenous factors affect
the extracellular collagen matrix in different ways,
causing degradation or synthesis of its components.
There are number of hormones, renin-angiotensin-
aldosterone system, different cytokines, matrix metallo-
proteinases and their tissue inhibitors [20, 21]. Interac-
tions and regulation of these molecules take part in left
ventricular remodeling process and conform to develop-
ment of cardiac healing, which is, also, the complex
process of well-defined and time-dependent continuous
and overlapping events. Despite of the fact that over the
last 30 years, achievements in pharmacological and
interventional treatment have reduced mortality in
patients with acute myocardial infarction, there is still
Fig. 1 a Paradigms dealing with mechanisms of cardiac remodeling after myocardial infarction. In the early phase of injury, ventricular
remodeling is an effect of infarct expansion; in late phase it involves reactive myocyte hypertrophy, interstitial fibrosis and left ventricular
dilatation. Changes of the extracellular collagen matrix in infarct heart play an important role in cardiac remodeling A huge number of
endogenous factors affect the extracellular collagen matrix in different ways, causing degradation or synthesis of its components. b
Cardiomyocyte necrosis triggers an activation of innate immune system and a cascade of inflammatory pathways. In response to ischemic injury
monocytes are recruited from the bone marrow and spleen to the heart and become monocyte-derived macrophages. Macrophages produce
pro- and anti-inflammatory factors, promote resorption of cellular debris, regulation of granulation tissue formation and neoangiogenesis. The
search of therapeutic target, which is able to prevent, limit or reverse adverse cardiac remodelingg is one of the most important and complicated
tasks of modern cardiology
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no effective method influencing process of myocardial
healing [22, 23]. Nowadays, the search of therapeutic tar-
get, which is able to prevent, limit or reverse adverse
cardiac remodeling and interrupt the development of left
ventricular dilatation, is still one of the most important
and complicated tasks of modern cardiology.
Suggested paradigms of cardiac remodeling became the
reason of wide use of anti-fibrotic strategies. ACE inhibition
[24], angiotensin receptor antagonism [25], mineralocortic-
oid blockade [26] and HMG-Coa-reductase inhibition [27]
reduce the development of progressive interstitial and peri-
vascular fibrosis, and contribute to beneficial cardiac
remodeling. However, some patients undergo progressive
heart failure despite of the anti-fibrotic treatment adminis-
tration. Obviously, more effective prevention of progressive
remodeling is compulsory [28].
The need to extend our knowledge about factors leading
to different clinical scenarios of myocardial infarction and
following complications has resulted in a research of
immuno-inflammatory pathways and molecular activities
as the basis for post-infarction remodeling.
Cardiomyocyte necrosis triggers an activation of innate
immune system and a cascade of inflammatory pathways.
Besides being some kind of «warning system», innate im-
munity is a complex molecular network which is sensitive
to different danger signals defined during cell necrosis and
degradation of extracellular matrix components. Recently,
macrophages (cells of the innate immune system) have be-
come a subject of scientific interest under both normal
and pathological conditions. Macrophages are an integral
part of innate immune response. They are equipped with
a set of pathogen recognition receptors, which can acti-
vate phagocytosis of pathogens and the secretion of cyto-
kines and chemokines. They present antigens on their cell
surface by major histocompatibility complex II (MHC II)
and interact closely with the adaptive immune system.
Monocytes/macrophages and resident macrophages are
key participants of inflammatory response, they produce
pro- and anti-inflammatory factors, promote resorption of
cellular debris, regulation of granulation tissue formation
and neoangiogenesis. In many ways, they determine
cardiac remodeling and healing after myocardial infarction
through secretion of proteases, growth factors, influence
cardiomyocyte apoptosis and proliferation.
Thus, we summarize data about the function of mono-
cytes and macrophages plasticity in myocardial infarc-
tion and outline potential role of these cells as effective
targets to control processes of inflammation, cardiac
remodeling and healing following acute coronary event.
Monocytes and macrophages in health and
disease
Monocytes are white blood cells developed in bone mar-
row from progenitor cells. From the bone marrow
monocytes go into blood. Under homeostatic conditions
they circulate in blood for 1–3 days [29]. Then mono-
cytes migrate into different organs, where they become
tissue macrophages and, also, give rise to dendritic cells.
Macrophages are one of major effectors of homeostasis
in many organs, including brain, liver, adipose tissue,
lymphatic system, gastro-intestinal tract [30]. They
realize functions such as phagocytosis, cytokine produc-
tion, antigen presentation.
Besides, monocytes can be attracted to the tissues by
infectious and inflammation conditions, when they begin
to play a key role in innate immune defense and are
involved in tissue remodeling and repair. Nowadays
functions of monocytes/macrophages and their subsets
are actively investigated in different clinical settings:
cancer, infectious, autoimmune, liver, kidney and cardio-
vascular diseases.
Origin of cardiac macrophages
It is known that a heart consists of several cell types,
including cardiomyocytes, cardiac fibroblasts, endothe-
lial and smooth muscle cells. In addition to these basic
types of cells, macrophages are also found in the
mammalian heart.
Previously believed, that blood-derived monocytes are
the only source of macrophages in the heart. This idea
has been disputed by recent work demonstrating the
yolk sac and fetal liver as a common sources of macro-
phages in adult tissues [31, 32]. According to these find-
ings, cardiac macrophages have their origin, at least to
some extent, in the yolk sac (YS). Initially YS-derived
macrophages show a common signature, later their dis-
tinct phenotype and functions are formed by local envir-
onment of the resident tissue [33]. Tissue macrophages
perform homeostatic functions and immune control.
Removal of damaged cardiomyocytes and pro-
inflammatory effects of macrophages are their routine
functions and has been shown in a number of articles
[30, 34]. Nevertheless, their role in inflammatory pro-
cesses in the heart needs to be defined.
It remains unknown, for how long YS-derived macro-
phages reside in adult tissues. In organs, such as the
brain and the liver, these cells are not substituted at
constant state and can persist independently of
hematopoietic stem cells [35]. However, replacement of
tissue macrophages by bone marrow-derived monocytes
is possible in a specific environment (e.g., intestine) or
as a result of bacterial infections [36]. In fact, the num-
ber of YS-derived resident macrophages in the mouse
heart also seems to be non-permanent and declines with
age. As mice grow older cardiac macrophages rate of
proliferation decreases and becomes insufficient to
preserve the resident macrophage pool [37]. Further-
more, resident macrophages in the heart are lost as a
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consequence of myocardial infarction. So, they need to
be substituted through monocyte recruited from the cir-
culation, or by local proliferation of resident cells. Fur-
ther experimental evidence will be required to define the
quantitative contribution of circulation monocytes to the
cardiac macrophage pool during aging and myocardial
injury conditions. Finally, it is still unknown to what ex-
tent effector functions of monocyte-derived macro-
phages are distinct from resident macrophages [38].
Undoubtedly, the findings will have implications for our
understanding of cardiac homeostasis and disease.
Activation and plasticity of monocytes/macrophages
One of the key monocyte/macrophages features, influen-
cing their functions, is their phenotypic and functional
plasticity [39, 40]. Under physiological and pathological
conditions these cells are able to modulate functional
and morphological characteristics, activate effector func-
tions. Thus, monocyte/macrophage “activation” process
gives rise to cell phenotypes with distinct and deter-
mined roles [41].
Currently, repeating the classification of T-helper cells,
which separates the cells on Th1 and Th2 types, macro-
phages are divided into two different subsets [42]: classic-
ally activated or interferon-γ (γ-IFN) mediated M1
macrophages exhibiting a strong bactericidal activity and
secreting large amounts of pro-inflammatory mediators,
and alternatively activated or interleukin-4/interleukin-
13(IL-4/IL-13) mediated M2 macrophages [43] showing a
high phagocytic activity and expressing IL-10, decoy type
II receptors, antagonist of receptor IL-1 (IL-1ra) [44].
Classically activated macrophages
The classical activation occurs after macrophage con-
tacts with activated T-helper 1 lymphocyte (Th-1). Pro-
duction of Th-1 cells is stimulated by viruses and some
bacterias, primarily intracellular pathogens. The stimulus
for their differentiation from immature effector T-
lymphocytes (Th-0) is secretion of IL-12 by dendritic
cells and IFN-γ by natural killers (NK-cells). After acti-
vation Th-cell begins to secrete a certain range of cyto-
kines, including IFN-γ. IFN-γ alone or together with
lipopolysaccharide or cytokines such as tumor necrosis
factor (TNF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) were first found mediators
of macrophage classical activation [45].
Initially, activated macrophage, meeting with the
pathogen, phagocytes it, exposes to processing, loads
proteins got in result of antigen processing to the mole-
cules of MHC II and presents complex of MHC II and
protein to its surface [46]. This process is accompanied
by the production of pro-inflammatory cytokines – IL-
12, IL-23, IL-27, TNF, chemokines – CXCL9, CXCL10,
CXCL11 and also by expressing surface markers -
cluster of differentiation (CD) 40, CD80, CD86 [27]. It
results in increase of nitric oxide, reactive oxygen spe-
cies, proteolytic enzymes release, including metallopro-
teinase (MMP)-1, -2, -7, -9 and -12 which degrade
collagen, elastin, fibronectin and other extracellular
matrix components [47]. Reactive oxygen species cause
cytotoxic effects of activated macrophages [28, 48].
Described mechanisms are aimed to host protection,
mediate resistance against intracellular parasites and tu-
mors, but, at the same time, during a long uncontrolled
or sudden intensive secretion conditions, they might be
the cause of cellular and extracellular components
destruction. Thus, classically activated macrophages
secrete pro-inflammatory cytokines, promote the devel-
opment of inflammation, extracellular matrix degrad-
ation and apoptosis.
Alternatively activated macrophages
Mechanism of macrophage alternative activation is follow-
ing. One of the first found sufficient signals to maintain
the macrophage activity were IL-4 and IL-13, secreted by
T-helper 2 lymphocytes (Th-2) [49]. It is now known that
other mediators can also drive alternative activation. For
example, IL-21 [50], IL-33 [51], IL-34 [52].
Alternatively activated macrophages are characterized
by expressing high levels of IL-10, IL-1ra, decoy type II
receptors [53], mannose, scavenger and galactose-type
receptors. These cells secrete the cytokines CCL17,
CCL22, CCL24 [54, 55], transforming growth factor-β
(TGF-β) [36], surface markers, such as CD163 [27],
stabilin-1 [56]. TGF-β, effecting fibroblasts, enhances
their ability to produce extracellular matrix components.
The cytokines such as platelet derived growth factor, in-
sulin like growth factor and TGF-β increase cell prolifer-
ation and stimulate angiogenesis. An important role in
angiogenesis plays vascular endothelial growth factor.
All these molecules are produced by alternatively acti-
vated macrophages [57]. Thus, M2 macrophages demon-
strate immune-regulatory and anti-inflammatory
properties; contribute to tissue remodeling, angiogenesis
and tumor progression [58]. It is necessary to mention,
that modern classification system subdivides M2 macro-
phages into M2a, M2b, M2c cells [59]. Classification the
M2 phenotype into subtypes highlights general proper-
ties and activation mechanisms of these cells. M2a and
M2c macrophages are crucial for promoting the adaptive
immune response, whereas suppression and regulation
of inflammation and immunity are mostly regulated by
M2b cells [60].
In this way, function of alternatively activated macro-
phages, unlike classically activated cells, is devoted to re-
pair process and resolution of inflammation. Different
stimuli like glucocorticoids, immunoglobulin complexes,
TGF-β, IL-10 generate formation of M2-like phenotypes
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that show some but not all the properties of alternatively
activated macrophages [25]. So, presence of macro-
phages with overlapping M1/M2 characteristics suggests
about remarkable plasticity of these cells.
Cardiac macrophages subsets in post-infarction
cardiac remodeling
There are three phases of the immune response to myo-
cardial ischemia: very early (hours), an early (hours-days)
and a late (weeks-months) phase [61]. Replacement of
the necrotic myocardium with granulation tissue takes
place during the initial inflammatory phase. The follow-
ing phases result in fibrosis and scar formation.
Monocytes/macrophages response to myocardial
ischemia
In response to ischemic injury monocytes are recruited
from the bone marrow and spleen to the heart and be-
come monocyte-derived macrophages [21] (Fig. 1b).
Nowadays functional properties of resident cardiac mac-
rophages are not clarified yet [43]. Mostly, it presents
technical difficulties in performance of specific genetic
manipulations to characterize functional contribution of
resident cells. One of the devised methods of macro-
phage function assessment is encapsulation of clodro-
nate with liposomes and its delivery into macrophages
via phagocytosis, resulting in macrophage depletion [62].
Several studies have shown cardioprotective functions of
cardiac macrophages in a mouse myocardial cryoinjury
model [63–65]. Application of the clodronate liposome
decreased vascular endothelial growth factor (VEGF)
[52] and TGF-β [53] expression, causing delayed myo-
cardial debris removal and impairment of neoangiogen-
esis. Thus, histological and cellular analysis
demonstrates that controlled recruitment and coordi-
nated activation of monocytes/macrophages are neces-
sary for optimal infarct healing because of promotion of
cellular debris resorption and apoptotic cells, degrad-
ation of extracellular matrix components, regulation of
granulation tissue formation, and neoangiogenesis
(Fig. 1b). In clinic, disbalance of these processes is ob-
served in progressive thinning of infarct area, chamber
dilatation and systolic dysfunction, or, on the other hand,
in increase myocardial stiffness, impaired relaxation and
progressive diastolic dysfunction.
Monocytes/macrophages subsets
Although monocyte/macrophages phenotype diversity is
not fully characterized, there is binary classification of
these cells for understanding their functions.
In mice models, blood monocytes were divided into two
subsets: Ly6Chi inflammatory monocytes recruited into in-
jured tissues show high levels of expression of the CC che-
mokine receptor CCR2, whereas expressing low levels of
the fractalkine receptor CX3CR1 (Ly-6ChiCCR2hiCX3CR-
low); and subset of Ly6ClowCCR2low/negCX3CR1hi mono-
cytes (CD14dimCD16+ in humans) [66].
Initial work suggested that early phase after infarction
is dominated by inflammatory Ly6Chi monocytes/macro-
phages. These cells produce inflammatory cytokines like
IL-1β, IL-6 and TNF-α, but, at the same time, realize a
cardioprotective function mediating proteolysis and
phagocytose cell debris during acute inflammatory phase
[21, 67, 68]. In contrast to Ly6Chimonocytes, Ly6Clow-
monocytes are recruited in the later post-infarct stages
and mediate myocardial healing through secretion of
anti-inflammatory cytokines and growth factors, such as
VEGF and TGF-ß, thus, contribute to myofibroblast ac-
tivation and neoangiogenesis [28, 55]. In its turn cardiac
fibroblasts can recruit monocytes via MCP-1-mediated
chemotaxis and adhesion to ICAM-1/VCAM-1, and in-
duce their differentiation to M1 or M2 macrophages
[69]. Recently it was shown that M2 polarization in in-
farcted mouse and human hearts is dependent on
macrophage-derived urokinase plasminogen activator
[70]. At the same time excess of urokinase plasminogen
activator promotes increased fibroblast migration and/or
proliferation. Also, hydrogen sulfide (H2S), a novel en-
dogenous gasomediator, stimulates M2 macrophage
polarization, thus.preventing post-infarction adverse
remodeling [71].
It is important to say, that studies devoted to descrip-
tion of mouse cardiac monocyte/macrophages subsets
and to refinement of its classification are continuing.
One of the recent study have described four subsets of
mouse cardiac CD45+CD11b+F4/80+ macrophages [72].
There were used surface markers, including Ly6C,
MHCII, CD11c and CCCR. According to the research,
Ly6Chi macrophages have been classified as M1 macro-
phages, and Ly6Clow or M2 macrophages were divided
into three subsets. It is worth noting that certain of M2
macrophages subsets demonstrated functions that
formerly have been considered only as M2 cells activity.
For example, one of the M2 macrophage population -
MHCIIlow, demonstrated a strong phagocytic activity;
another population – MHCIIhiCD11clowCCR2- showed
remarkable antigen-presenting function; finally, MHCII-
hiCD11chiCCR2hi macrophages had pro-inflammatory
phenotype. In another study Shiraishi et al.[73] identified
CD206+F4/80+CD11b+ M2-like macrophages in the
murine heart which determined the repair of infarcted
heart due their fibroblast activation function. Further-
more, the authors suggested IL-1α and osteopontin as
mediators of M2-like macrophage–induced fibroblast
activation. The information concerning monocytes/mac-
rophages subsets is summarized in Table 1.
New data once again suggest that there are still a lot
of questions about monocytes/macrophages phenotypes
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and functions under physiological and pathophysio-
logical conditions, including post-infarction cardiac
remodeling.
Monocytes/macrophages plasticity
In that way, the clear categorization of monocyte/macro-
phages subsets into distinct phases and functions after
infarction has been disputing. The developmental rela-
tionship between monocyte subsets and macrophage
polarization into phenotypically and functionally distinct
cells requires further studies. Undoubtedly, monocytes/
macrophages have peculiar plasticity that allows them to
phenotypically polarize in response to microenviron-
mental signals according to specific M1 or M2 func-
tional programs. New information, concerning plasticity
of these cells and signals that might regulate it, is con-
tinuing to accumulate.
It has been reported, that Ly6Clow development and
survival of monocytes depend on the transcription factor
Nr4a1 [74]. Absence of Ly6Clow monocytes in Nr4a1-
deficient animals does not interrupt the bi-phasic in-
flammatory response. It might be explained by the
concept that Ly6Clow cells derive from Ly6Chi mono-
cytes, which demonstrate high plasticity and develop
into either pro-inflammatory or anti-inflammatory
monocytes [41, 55]. Moreover, there are some findings
showing that inflammatory Ly6Chi monocytes are pre-
dominantly attracted to the infarct area not only in the
first days of infarction but throughout the course of
post-infarct remodeling [75]. In another recent study,
the authors demonstrated that cardiosphere-derived cells
favored heart repair by switching the macrophages from
a pro-inflammatory phenotype (M1) into an anti-
inflammatory phenotype (M2) [76]. Cardiosphere-
derived cells administration decreased M1 macrophages
and neutrophils but increased M2 macrophages in the
infarcted heart.
Certainly, one of the main signal that can influence
the plasticity of monocytes/macrophages is phagocytosis
of apoptotic cells after acute myocardial infarction. M1
macrophages are able to change its phenotype into M2
macrophages when recognizing of apoptotic cells occurs
[77]. Impaired resolution of inflammation may express
in prolonged M1 macrophage activation influencing on
myocardial infarction outcomes, including development
of adverse cardiac remodeling [55, 78].
Thus, nowadays studies demonstrate cardioprotective
role of optimal monocytes/macrophages activation and
polarization. That fact allows considering control of re-
cruitment of monocytes/macrophages subpopulations
and its plasticity modulation as a new therapeutic ap-
proach for the timely influence on post-infarction
inflammation and following cardiac remodeling (Fig. 1b).
New experimental therapeutic approaches for
prevention of post-infarction cardiac remodeling
To date modern knowledge about the response of innate
immune system and the role of inflammation following
myocardial ischemia provides new experimental oppor-
tunities in studying and development of new therapeutic
targets that could be able to prevent adverse cardiac re-
modeling and heart failure.
Macrophage as a therapeutic target for post-infarction
myocardial repair
Playing a significant role in the myocardial infarction
pathophysiology, monocytes/macrophages are consider-
ing as a potential therapeutic target in promoting of
myocardial healing. Despite the considerable progress in
characterizing factors regulating monocyte/macrophage
polarization, nowadays we are at the beginning of under-
standing the spatiotemporal relationships and functions
of the various macrophage subsets in the post-infarction
cardiac remodeling [79, 80].
Different stages of monocyte/macrophage vital activity
are actively suggested as targets to modulate its activation
and polarization. One of the sides is blocking the attrac-
tion of inflammatory monocytes. Kempf et al. [81, 82]
have shown that in the infarct myocardium stimulation of
growth differentiation factor-15 (GDF-15) is occurred,
which plays an important role in controlling of inflamma-
tory cell recruitment. GDF-15 is an anti-inflammatory
Table 1 General characteristics of monocytes/macrophages
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cytokine, which is able to limit the tissue damage by inhib-
ition the attraction of monocytes to the post-infarction in-
flammation area and reduce episodes of left ventricular
rupture. Blocking of the inflammatory monocytes recruit-
ment can be also achieved by exposure to chemokines,
which leads to a decrease of circulating inflammatory
monocytes (e.g., removal of receptor CCR2), or by inhibit-
ing their implication to ischemic area (e.g., CXC chemo-
kine receptor type 6, CXCR6; macrophage migration
inhibitory factor, MMIF). Positive effect on cardiac remod-
eling can be achieved by reduction of CCR2+ monocytes
due to attenuating inflammatory response after myocar-
dial infarction [83, 84]. Moreover, destruction of CXCR6
receptors reduces the amount of CD11b+ cells in the in-
farcted area and resulting in improved cardiac function
and prevention of adverse myocardial remodeling through
breaking autophagis response [85]. Inhibition of MMIF af-
fects the apoptosis and other signaling cascades. It is im-
portant to note, that plasma MMIF levels are associated
with the infarct size and the severity of cardiac remodel-
ing. However we have to remember, that MMIF blockade
is not specific, and among other results, it leads to neutro-
phil migration reduction [86].
Another approach to affect monocyte/macrophage func-
tion is the idea of changing their microenvironment. As re-
cently shown, macrophage phenotypes and functions are
formed by the microenvironment of the resident organ
[87]. In addition, resident macrophages interact with cells
of the adaptive immune system. There is a positive effect
on wound healing and remodeling due to modulation of
monocyte/macrophage differentiation in the setting of
myocardial infarction by regulatory T-cells [88]. B-
lymphocytes interact with monocytes during cardiac repair
process. B-cells contribute to recruitment of Ly6Chi mono-
cytes to the myocardial infarction area by secretion CCL7.
Depletion of B-cells leads to decrease of circulating mono-
cytes and inflammatory Ly6Chi monocytes in myocardium
and it results in the improvement of contractile function
and reduction of infarct area [89]. Though, further experi-
mental and clinical data are required to study exact mecha-
nisms of the cross-reactions between the adaptive immune
system and monocytes/macrophages and their therapeutic
potential in post-infarction cardiac remodeling.
Finally, resident macrophages can be affected by intra-
cellular signals that, for example, can stimulate the
proliferation or apoptosis. Effecting expression of the
transcription factor MafB may decelerate macrophage
apoptosis during inflammatory conditions [90]. Another
example is IL-4, which causes accelerated proliferation
of the resident macrophages [91].
MicroRNAs as targets for prevention of remodeling
Micro ribonucleic acids (miRNAs) are involved in alteration
the cellular gene expression response. Significance of
miRNAs was shown in multiple processes including tissue
repair and injury, immune and inflammatory responses [92,
93]. miRNAs control the development, differentiation, and
function of monocytes/macrophages by targeting numerous
molecules participating in these processes. Transcription
factors playing a crucial role in macrophage polarization
are controlled by specific miRNA. The signal transducer
and activator of transcription 1 (STAT 1) and interferon-
regulatory factor 5 (IRF 5) dictate M1 macrophage
polarization [94]. M2 macrophage polarization is directed
by STAT 6, peroxisome proliferator-activated receptor-γ
(PPARγ), and IRF 4 [94]. For instance, it was demonstrated,
that miR-125a-3p and miR-26a-2 are expressed in M1 mac-
rophages, whereas miR-193b, miR-27a, miR-29b-1, miR-
132 and miR-222 are expressed in M2 subset [95]. Thus,
miRNAs play an important role in regulation of mono-
cytes/macrophages key functions, including their role in
post-infarction cardiac remodeling (Table 2) [96].
miRNAs are important regulators of cellular gene pro-
grams in cardiovascular disease, and its targeting may be-
come a useful approach to prevent post-infarction cardiac
remodeling [97–99]. Reactivation of the fetal miRNA trig-
gers pathological changes leading to progressive remodel-
ing and heart failure by contribution to alterations of gene
expression [100]. Analysis of microRNAs in the heart has
to focus not only on cardiomyocytes, but also on fibro-
blasts, inflammatory cells, endothelial cells, and smooth
muscle cells [101]. It has been detected that miRNAs in-
volved both early and late in cardiac healing and remodel-
ing processes during and after myocardial ischemia.
Early after myocardial ischemia reperfusion, miR-21 was
localized in the fibroblast-enriched infarct region and may
regulate the expression of matrix metalloprotease-2 in the
infarct area via its target PTEN (phosphatase and tensin
homologue) [102]. Possibly, in that way, up-regulation of
miR-21 plays a protective role in the early phase of
myocardial infarction [103].
Table 2 miRNAs in regulation of monocytes/macrophages
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Targeting other miRNAs deregulated after cardiac
ischemia was associated with therapeutic benefit: miR-29
appeared to be involved in fibrosis development,
whereas miR-92a is an endothelial miR regulating angio-
genesis [104, 105] and miR-24 induced endothelial cell
apoptosis and inhibited angiogenesis [106]. These effects
were mediated through targeting of the endothelium-
enriched transcription factor GATA2 and the p21-acti-
vated kinase-4. Well-timed treatment after myocardial
infarction with an antagomir (synthetic molecule that is
complementary to a specific miRNA) against miR-24 re-
duced left ventricular remodeling in mice and improved
cardiac function. In that way, new knowledge concerning
mRNAs will be decisive in developing miRNA-based
therapies. Considering monocyte/macrophage
polarization as an important factor of wound healing
after myocardial ischemia, miRNA regulation of myeloid
cells may be significantly involved in healing and remod-
eling after myocardial infarction; however, these investi-
gations are in their beginning stage and have an
experimental character [107].
Conclusion
Despite the progress of experimental studies devoted to
the response of innate immune system and the role of in-
flammation following myocardial infarction, there is no
significant advancement in clinical studies. In addition not
all experimental data can be extended to the clinical. That
is why it is important to verify experimental data concern-
ing monocyte/macrophage activation and polarization in
post-infarction cardiac remodeling in clinical material.
Identifying effective markers of different monocyte/
macrophage subsets in patients with myocardial infarction
might be the first step in our knowledge enrichment. The
following question includes study of molecules and mech-
anisms that are able to regulate the balance between M1
and M2 macrophages and become effective targets in pre-
vention of adverse post-infarction cardiac remodeling.
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